Table 1.
Baseline Participant Demographic and Clinical Characteristics
| Characteristic | D/C/F/TAF (N = 109) |
|---|---|
| Demographic characteristics | |
| Age, y, median (range) | 28 (19–66) |
| Male sex | 95 (87) |
| Race | |
| White | 65 (60) |
| Black/African American | 35 (32) |
| Other | 9 (8) |
| Body weight, kg, median (range) | 78.8 (46–155) |
| Clinical characteristics | |
| HIV-1 RNA, No. | 108a |
| Median (range), copies/mL | 38 700 (19b–144 000 000) |
| ≥100 000 copies/mL | 27 (25) |
| CD4+ cell count, No. | 108a |
| Median (range), cells/µL | 369 (7–1082) |
| <200 cells/µL | 23 (21) |
| HIV acquisition risk factorc | |
| Heterosexual contact | 17 (16) |
| Intravenous drug use | 2 (2) |
| MSM | 82 (75) |
| Multiple | 5 (5) |
| Other | 3 (3) |
| Time from diagnosis to screening/baseline, d, median (range) | 5 (0–14) |
| Enrolled within 48 h of diagnosis | 34 (31) |
| Duration of infection, No.c | 108b |
| Acute infectiond | 13 (12) |
| Early infectione | 43 (40) |
| Chronic infectionf | 34 (32) |
| Unknown | 18 (17) |
| WHO clinical stage of HIV infection | |
| Stage 1 (asymptomatic) | 93 (85) |
| Stage 2 (mild symptoms) | 11 (10) |
| Stage 3 (advanced symptoms) | 5 (5) |
| CDC disease classificationc | |
| Stage A | 100 (92) |
| Stage B | 6 (6) |
| Stage C | 3 (3) |
| General characteristicsg | |
| Active nicotine use | 45 (41) |
| Active alcohol consumption | 90 (83) |
| Insurance coverage | 67 (61) |
| Employment statusc | |
| Employedh | 87 (80) |
| Unemployed | 16 (15) |
| Otheri | 6 (6) |
| Social supportc | |
| Case managerj | 4 (4) |
| Family/friends/multiple | 100 (92) |
| Missing | 5 (5) |
| Current housing situationc | |
| Own | 17 (16) |
| Rent | 51 (47) |
| Live with friends/family or other | 41 (38) |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: CDC, Centers for Disease Control and Prevention; D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; HIV, human immunodeficiency virus; HIV-1, human immunodeficiency virus type 1; MSM, men who have sex with men; WHO, World Health Organization.
aOne participant had missing values due to a shipping error of the screening/baseline samples.
bOne participant was HIV-1 negative (false-positive fourth-generation test).
cPercentages may not total 100% due to rounding.
dAcute infection was defined as HIV-1 antibody negative and HIV-1 RNA positive/ p24 positive.
eEarly infection was defined as HIV-1 antibody positive and suspected infection ≤6 mo prior to screening/baseline.
fChronic infection was defined as HIV-1 antibody positive and suspected infection >6 mo prior to screening/baseline.
gThe most common (≥15% of participants) medical history events were seasonal allergy (24%), hypertension (17%), anxiety (17%), and syphilis (16%).
hEmployed includes employed full time for wages, employed part time for wages, and self-employed.
iOther includes retired, short- or long-term disability, student, and other.
jCase manager who helps with medication administration.